INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 426m ago
HOUSE PTR25m ago
SEC 13F25m ago
ROBINHOOD CHAIN25m ago
SEC FORM 4/Open-market purchaseVerified data

Durso Jerome Benedict bought ALT

Director, President and CEO · Altimmune, Inc. · Common Stock, par value $0.0001

Side
BUY
Value
$44K
Shares
15.0K
Price
$2.95
Executed
Aug 13, 2026
Disclosed
Aug 13, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Aug 13 executedAug 13, 2026 disclosed

ALT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
33/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+9 / 25

    $44K reported value · 31.6% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ALT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    HG
    Howarth Alex G.Director
    ALTAltimmune, Inc.
    Grant or award
    		A—
    160.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GP
    Greenleaf PeterDirector
    ALTAltimmune, Inc.
    Grant or award
    		A—
    160.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MT
    Menziuso Richard ThomasPrincipal Accounting Officer
    ALTAltimmune, Inc.
    Grant or award
    		A—
    36.2K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MT
    Menziuso Richard ThomasPrincipal Accounting Officer
    ALTAltimmune, Inc.
    Grant or award
    		A—
    84.5K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    LL
    Lawver Teri LDirector
    ALTAltimmune, Inc.
    Grant or award
    		A—
    48.8K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Grant or award
    		A$14K
    4,571 sh
    		Jan 31, 2026Feb 2, 2026
    traded Jan 31, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$26K
    4,229 sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    21
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$29K
    4,748 sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    21
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$24K
    4,373 sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$21K
    3,855 sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    21
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    21
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    41
    PW
    Pisano WayneDirector
    ALTAltimmune, Inc.
    Open-market purchase
    		BUY$20K
    5,000 sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    44
    DB
    Durso Jerome BenedictDirector
    ALTAltimmune, Inc.
    Open-market purchase
    		BUY$52K
    12.5K sh
    		Dec 22, 2025Dec 22, 2025
    traded Dec 22, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001698665-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 13, 2026
    Published
    Aug 13, 2026
    Ingested by INSIDER
    Nov 5, 02:23 UTC
    Last re-read
    Nov 5, 02:23 UTC

    Extracted facts

    Filer
    Durso Jerome Benedict
    Role
    Director, President and CEO
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    Altimmune, Inc.
    Ticker
    ALT
    Shares
    15.0K
    Price per share
    $2.95
    Value
    $44,250
    Execution date (reported)
    Aug 13, 2026
    Owned after transaction
    62.5K shares
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 15.0K
    • Price: $2.95

    = $44,250

    What this establishes

    Durso Jerome Benedict filed this Form 4 reporting a open-market purchase of ALT on Aug 13, 2026. It became public on Aug 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President and CEO
    Durso Jerome Benedictcik:0001698665
    Issuer
    Altimmune, Inc.cik:0001326190

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.